Valentina Fanotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6924661/publications.pdf

Version: 2024-02-01

50 papers	1,062 citations	471509 17 h-index	414414 32 g-index
54 all docs	54 docs citations	54 times ranked	2179 citing authors

#	Article	IF	Citations
1	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Frontiers in Pharmacology, 2017, 8, 354.	3.5	165
2	Pattern of metastasis and outcome in patients with breast cancer. Clinical and Experimental Metastasis, 2015, 32, 125-133.	3.3	144
3	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
4	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 368-377.	7.3	61
5	Gastric cancer: Translating novels concepts into clinical practice. Cancer Treatment Reviews, 2019, 79, 101889.	7.7	60
6	Sarcopenia in gastric cancer: when the loss costs too much. Gastric Cancer, 2017, 20, 563-572.	5.3	47
7	Do platinum salts fit all triple negative breast cancers?. Cancer Treatment Reviews, 2016, 48, 34-41.	7.7	46
8	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
9	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 2019, 11, 1243.	3.7	40
10	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
11	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	5.3	32
12	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
13	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infectious Agents and Cancer, 2020, 15, 42.	2.6	29
14	Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clinical and Experimental Metastasis, 2015, 32, 819-833.	3.3	28
15	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opinion on Biological Therapy, 2017, 17, 365-374.	3.1	27
16	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	3.7	27
17	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews, 2019, 72, 7-14.	7.7	25
18	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. Oncologist, 2020, 25, 661-668.	3.7	21

#	Article	IF	Citations
19	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	3.3	18
20	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. Clinical Nutrition, 2021, 40, 286-294.	5.0	17
21	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	1.9	11
22	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. Future Oncology, 2017, 13, 2265-2275.	2.4	10
23	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. Journal of Clinical Oncology, 2014, 32, e12532-e12532.	1.6	9
24	Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 205-213.	2.4	8
25	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. Annals of Oncology, 2016, 27, vi560.	1.2	7
26	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. PLoS ONE, 2021, 16, e0259137.	2.5	7
27	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of Geriatric Oncology, 2019, 10, 591-597.	1.0	6
28	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast, 2018, 40, 45-52.	2.2	4
29	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	2.4	2
30	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. Journal of Clinical Oncology, 2018, 36, e13079-e13079.	1.6	2
31	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
32	2153 Analysis ofthe molecular profile of brain metastases from colorectal cancer and concordance with matched primary tumors. European Journal of Cancer, 2015, 51, S384-S385.	2.8	1
33	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. Journal of Clinical Oncology, 2021, 39, e16102-e16102.	1.6	1
34	1227 Risk of unplanned presentations and hospital admission of breast cancer outpatients. European Journal of Cancer, 2015, 51, S182.	2.8	0
35	2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy. European Journal of Cancer, 2015, 51, S454-S455.	2.8	0
36	1860 Last-line treatment of advanced breast cancer: Which clinical characteristics maypredict the outcome?. European Journal of Cancer, 2015, 51, S285.	2.8	0

#	Article	IF	Citations
37	May mutational status influence the metastatic pattern of colorectal cancer patients?. Annals of Oncology, 2016, 27, iv42.	1.2	0
38	Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice?. Annals of Oncology, 2016, 27, iv63.	1.2	0
39	Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. Annals of Oncology, 2016, 27, iv63.	1.2	0
40	Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the â€œGastric Lifeâ€•nomogram. Annals of Oncology, 2017, 28, vi46-vi47.	1.2	0
41	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Annals of Oncology, 2017, 28, vi45.	1.2	0
42	PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome. Annals of Oncology, 2019, 30, v238.	1.2	0
43	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. Current Clinical Pathology, 2019, , 121-132.	0.0	0
44	Serum Biomarkers in Gastric Cancer. Current Clinical Pathology, 2019, , 107-117.	0.0	0
45	P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer. Annals of Oncology, 2020, 31, S170.	1.2	0
46	Treatment during the last month of life in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, e17649-e17649.	1.6	0
47	Abstract P2-08-06: Usefulness of the pre-treatment neutrophil-to-lymphocyte ratio in predicting first-line progression free-survival in triple-negative breast cancer patients. , 2016, , .		0
48	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. Journal of Clinical Oncology, 2016, 34, e15553-e15553.	1.6	0
49	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. Journal of Clinical Oncology, 2017, 35, e12010-e12010.	1.6	0
50	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€”Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	1.6	0